Physician profile
Scott A Thomas
NPI 1710033394
$4,014.79
in general payments reported to CMS, 2019-2025
22 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,653 · 2020: $326 · 2021: $45.72 · 2022: $674 · 2023: $161 · 2024: $667 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,316.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,094.92 | 2019-2022 | |
| Alcon Vision LLC | $890.85 | 2019-2025 | Argos, Clareon, Centurion |
| Abbvie INC. | $316.99 | 2022-2025 | Vraylar |
| Rxsight INC | $264.87 | 2022-2024 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Aerie Pharmaceuticals, INC. | $256.95 | 2019-2020 | |
| Allergan, INC. | $188.83 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $149.16 | 2019-2021 | |
| Biotissue Holdings INC. | $128.16 | 2022 | |
| Genentech USA, INC. | $127.00 | 2019 | |
| Dompe US, INC. | $121.85 | 2024 | Oxervate |
| Novartis Pharmaceuticals Corporation | $89.72 | 2019-2022 | |
| Pfizer INC. | $59.34 | 2023-2025 | |
| Akorn, INC. | $45.40 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $43.48 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $40.13 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $35.37 | 2022 | |
| Ironshore Pharmaceuticals INC. | $32.31 | 2019 | |
| Thea Pharma INC. | $31.31 | 2022 | |
| Horizon Therapeutics Plc | $30.23 | 2023 | Tepezza |
| Takeda Pharmaceuticals U.S.A., INC. | $28.99 | 2019 | |
| Amgen INC. | $19.78 | 2024 | Tepezza |
| New World Medical,INC. | $19.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.